Literature DB >> 11899308

Vancomycin intermediate-resistant Staphylococcus aureus (VISA).

N C Miller1, R C Rudoy.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) has been an infectious disease problem since the early 1980s and until recently was uniformly susceptible to vancomycin, the drug known as the "last resort." Recent reports indicate that Staphylococcus aureus has continued to mutate and has developed intermediate resistance to vancomycin (VISA). This article lists some of the potential clinical manifestations of Staphylococcus aureus as well as a possible explanation of the phenomenon of antibiotic resistance. The reported cases of VISA are reviewed, and intervention strategies for prevention and control are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11899308     DOI: 10.1097/00006416-200019060-00009

Source DB:  PubMed          Journal:  Orthop Nurs        ISSN: 0744-6020            Impact factor:   0.913


  1 in total

1.  The clinical significance of silent mutations with respect to ciprofloxacin resistance in MRSA.

Authors:  Chih-Cheng Lai; Chi-Chung Chen; Ying-Chen Lu; Yin-Ching Chuang; Hung-Jen Tang
Journal:  Infect Drug Resist       Date:  2018-05-03       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.